Global Inactivated Vaccines Market is valued at USD 5417.4 Million in 2021 and expected to reach USD 6850.6 Million by 2028 with a CAGR of 3.41% over the forecast period.
Global Inactivated Vaccines Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing use of inactivated vaccines, rising number of cases of Covid-19 and other infectious diseases, growing number of clinical trials of vaccines are major factors anticipated to drive the growth of the Global Inactivated Vaccines Market.
Dead or inactivated virus or bacteria-containing vaccines are called inactivated vaccines and thus they are differing from live but attenuated vaccines. Inactivated vaccines are another kind of vaccine, where the virus is inactivated during the method of creating the vaccine. Inactivated vaccines aren't strongly influenced by antibodies within the host body, compared to measure vaccines. Inactivated vaccines require two doses the primary dose is that the one that prepares the system to reply, but a protective immune reaction doesn't develop until the second or later doses. Because the virus is dead during the making of the vaccine, they interact with the system differently than live, attenuated vaccines. The immune reaction to measure vaccines is analogous to encountering the virus itself, whereas inactivated vaccines show little or no cellular immunity. This also means inactivated vaccines are often wont to boost to. Inactivated vaccines were first developed within the late 1800s and early 1900s for cholera, plague, and typhoid.
The Covid-19 pandemic has shown a positive impact on the growth of global inactivated vaccines market. The inactivated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being tested at various clinical stages as inactivated vaccines have low risk and easy in production. The need for development of vaccine against COVID-19 and research in inactivated vaccines positively impacted the market.
The global inactivated vaccines market is segmented into on the basis of type, and method of inactivation, route of administration, distribution channel, end-user and region & country level. On the basis of type, the global inactivated vaccines market is classified into bacterial vaccines and viral vaccines. On the basis of route of administration, the global inactivated vaccines market is divided into intravenous, oral, subcutaneous and others. On the basis of distribution channel, the market is divided into hospital pharmacy, retail pharmacy and other. On the basis of end-user, the global inactivated vaccines market is divided into hospitals, specialty clinics and others.
Some of the key players for global inactivated vaccines market are
On October 26th, 2021; Valneva’s Covid-19 inactivate vaccine Aces French vaccine maker Valneva announced promising phase III clinical trial. The vaccine consisted of killed or ‘inactivated’ version of SARS-CoV-2, the virus liable for Covid-19. The vaccine was tested in adults aged 18 and up in a phase III clinical trial and its protection was compared to AstraZeneca’s COVID-19 vaccine. The trials of Valneva’s candidate had shown fewer side effects than those given AstraZeneca’s vaccine, particularly those over 30. COVID-19 vaccines currently on the market in Europe is supported either adenoviral vector, including vaccines from AstraZeneca and Johnson & Johnson, or newer messenger mRNA (mRNA) technology including vaccines from BioNTech/Pfizer and Moderna. Their exclusive target is that the spike protein on the surface of the virus, which the virus uses to enter cells. However, the protein mutates far more quickly than other parts of the virus, which increases the likelihood of the virus becoming immune to the vaccine. Inactivated vaccines like Valneva’s candidate allow the system to focus on a wider range of viral proteins than approved vaccines, which could make them harder for the virus to resist.
On June 20th, 2021; Intravacc, a supplier of translational innovative work of immunizations for irresistible infections and therapeutics, said the Chinese National Medical Products Administration (NMPA) officially known as the Chinese FDA had allowed Sinovac Biotech market approval for its Sabin-IPV (sIPV) inactivated polio vaccine, created by Intravacc and out-authorized to Sinovac. This multivalent polio vaccine was created by Intravacc to turn out low and middle-income nations with the valuable chance to deliver their own protected polio vaccine with regards to the worldwide polio eradication drive.
One of the major factors driving the growth of the global inactivated vaccines market is rising prevalence of infectious diseases. Growing prevalence of infectious disease is making a continuous danger for public health in practically all the countries. Cholera, Polio, Influenza, COVID-19, Hepatitis A, and Pertussis are some of the mostly noticed irresistible infections across infectious diseases across the world and predominance rate for these diseases is developing significantly. The research has been carried for the technique of using inactivated virus for making vaccine against COVID-19 and other infectious diseases. Inactivated vaccines are really used to treat infectious diseases and accordingly developing occurrences of these diseases is driving the development of this market. For instance, according to World Health Organization (WHO), on 18th February 2022, there have been 418,650,474 confirmed cases of COVID-19, and 5,856,224 deaths.
In addition, another major factor supplementing the growth of global inactivated vaccines market is increasing use of inactivated vaccines. The inactivated vaccines were used for different diseases in hospitals as it has more advantages than live vaccines. The inactivated vaccines contain dead bacteria or virus thus it can be shipped and stored which makes transport easier, particularly in parts of the world where resources are limited. As there was no side effects and risk of disease in inactivated vaccines, they are given to most. However, there was risk involved in live vaccines, as there is a small chance that a virus can replicate and cause illness in some people. Hence inactivated vaccines were preferred over live attenuated vaccines and this factor is driving the market growth of the global inactivated vaccines over the forecast period.
Moreover, supportive government initiatives for vaccine development are also augumenting the growth of the global inactivated vaccines market. Government support has been assuming significant part in the vaccine advancement and improvement because of the essential role played by vaccines in the medical care practices. To make sure public health, governments from different geologies have been coming up with measures to offer opportunities in vaccine developments. For example; as of June 2020, the International Monetary Fund assessed that around United States dollars (US$) 11 trillion had been allocated worldwide as financial help to the COVID-19 response.
However, inactivated vaccines take relatively long production time and also require two or three vaccine doses for immunity development which may hamper the inactivated vaccines market growth. In spite of that, research and development and rising research and development activities for inactivated vaccines can provide various opportunities for the further growth of the global inactivated vaccines market.
North America is expected to dominate the global inactivated vaccines market due to rising prevalence of Covid-19, increasing adoption of vaccines, government initiatives in vaccines development and high investment on R & D activities in this field in this region. Also, vaccination is the key for controlling the spread of covid-19 strains. Thus, need of vaccine and demand for vaccine is increased due to increasing number of covid-19. For instance; as per Worldometer; there have been 1609,651 active cases as of May 9th, 2022 of Covid-19. In addition to that, rising adoption of inactivated vaccines because of safety also drives the inactivated vaccines market growth. For instance; in 2019, UNICEF (United Nations Children’s Fund) introduced inactivated polio vaccines (IPV into all countries’ routine immunization programmes, for fight against poliovirus. Moreover, supportive government initiatives are likely to provide market growth as new vaccines programmes are planned by government for preventing infectious diseases and by supporting research in vaccines for new innovative vaccine production.
Asia Pacific is expected to be largest market for the global inactivated vaccines market due to increasing research on vaccines, rising awareness about vaccines and government funding for vaccine development in this region. The emerging countries such as India is continuously researching on vaccines which is likely expected to accelerate the market growth. In addition, rising awareness about vaccines in people which led to more people is getting vaccinated and market of inactivated vaccine is expected to grow. Furthermore, rising government funding is also expected to augment the market growth over the forecast period. For instance; as per the news published on February 14th, 2022, Indian government spent Rs. 250 Crore on COVID-19 vaccine research as in April 2020.
Middle East and Africa
|2015 - 2020
|2021 - 2028
|Market Size in 2021:
|USD 5417.4 Million
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 6850.6 Million
|Tables, Charts & Figures:
|Key Players / Manufacturers
|Merk, GlaxoSmithKline, Johnson and Johnson, Pfizer, Sanofi, AstraZeneca, CSL Ltd, Abbott, and Serum Institute of India, and others.
|By Type, By Route of Administration, By Distribution Channel, By End-User
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®